SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:786cb6bb-6825-4ace-b977-0cc1e1482501"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:786cb6bb-6825-4ace-b977-0cc1e1482501" > Longitudinal change...

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

Majbour, Nour K. (författare)
Amsterdam UMC - Vrije Universiteit Amsterdam,Hamad Bin Khalifa University
Vaikath, Nishant N. (författare)
Lund University,Lunds universitet,Neural plasticitet och reparation,Forskargrupper vid Lunds universitet,Neural Plasticity and Repair,Lund University Research Groups,Hamad Bin Khalifa University
Eusebi, Paolo (författare)
University of Perugia
visa fler...
Chiasserini, Davide (författare)
University of Perugia
Ardah, Mustafa (författare)
United Arab Emirates University
Varghese, Shiji (författare)
United Arab Emirates University
Haque, M. Emdadul (författare)
United Arab Emirates University
Tokuda, Takahiko (författare)
Kyoto Prefectural University of Medicine
Auinger, Peggy (författare)
University of Rochester
Calabresi, Paolo (författare)
University of Perugia
Parnetti, Lucilla (författare)
University of Perugia
El-Agnaf, Omar M A (författare)
Hamad Bin Khalifa University
visa färre...
 (creator_code:org_t)
2016-10-06
2016
Engelska 8 s.
Ingår i: Movement Disorders. - : Wiley. - 0885-3185. ; 31:10, s. 1535-1542
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Parkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease-modifying therapies. In this article, we investigated the longitudinal changes of CSF α-synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. Methods: We used our newly developed enzyme-linked immunosorbent assay systems for measuring different forms of α-synuclein, such as oligomeric-α-synuclein, phosphorylated-α-synuclein at serine 129, or total-α-synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n = 121). CSF Alzheimer's disease biomarkers (total-tau, phosphorylated-tau, Aβ40, and Aβ42) were also measured for this cohort. Results: Interestingly, total-α-synuclein and oligomeric-α-synuclein levels significantly increased during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow-up period, whereas phosphorylated-α-synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric-α-synuclein/total-α-synuclein ratio and a worsening of motor signs, in particular in the postural-instability and gait-difficulty dominant PD group. A strong positive correlation between the changes in CSF total-α-synuclein and oligomeric-α-synuclein during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r = 0.84, P <.001). Conclusion: Our data show that CSF α-synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

alpha-synuclein
biomarkers
DATATOP
oligomers
Parkinson's disease

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy